Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

ASR-3001

From Wikipedia, the free encyclopedia

Pharmaceutical compound
ASR-3001
Clinical data
Other namesASR3001; 5-MeO-iPALT; 5-MeO-ALiPT; 5-Methoxy-N-isopropyl-N-allyltryptamine; 5-Methoxy-N-allyl-N-isopropyltryptamine
Routes of
administration		Oral[1]
Drug classSerotonin receptor agonist;Serotonin5-HT2A receptoragonist;Serotonergic psychedelic;Hallucinogen
ATC code
  • None
Legal status
Legal status
  • In general Unscheduled
Pharmacokinetic data
Onset of action≤15 minutes (as fast as 6–8 minutes)[1][2][3][4]
Duration of action1.5–2.5 hours[4][1]
Identifiers
  • N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-prop-2-enylpropan-2-amine
PubChemCID
Chemical and physical data
FormulaC17H24N2O
Molar mass272.392 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC1=CNC2=C1C=C(C=C2)OC)CC=C
  • InChI=1S/C17H24N2O/c1-5-9-19(13(2)3)10-8-14-12-18-17-7-6-15(20-4)11-16(14)17/h5-7,11-13,18H,1,8-10H2,2-4H3
  • Key:MRWWDVFDOFUYKB-UHFFFAOYSA-N

ASR-3001, also known as5-methoxy-N-isopropyl-N-allyltryptamine (5-MeO-iPALT), is aserotonin receptor agonist andserotonergic psychedelic of thetryptamine and5-methoxytryptamine families which is under development for the treatment ofpsychiatric disorders.[5][1][2][3][6] It is a closeanalogue of related psychedelic tryptamines like5-MeO-DALT,5-MeO-DiPT, and5-MeO-MiPT.[6] The drug is takenorally.[1]

Use and effects

[edit]

ASR-3001 is said to beorally active, fast- and short-acting, and to induce "an internal psychedelic cognitive state [or head space] with little or no sensory [or visual] involvement".[1][2][3][4] More specifically, it is said to have an absence ofopen-eye andclosed-eye visuals.[4] These properties are expected to allow ASR-3001 to serve as a potential "entry point" for people reluctant to undergo a fully immersive psychedelic experience that includesvisuals.[1][4] ASR-3001 is said to be internally psychedelic as opposed toentactogenic.[4] Itsdose range is 8 to 14 mg (or perhaps up to 10 mg), itsonset is within 15 minutes or as fast as 6 to 8 minutes, and itsduration is short at about 1.5 to 2.5 hours (90–150 minutes).[1][2][3][4] Along with4-HO-DiPT, it appears to be one of the shortest-acting oral psychedelics known.[4][1][7][8]

Interactions

[edit]
See also:Psychedelic drug § Interactions, andTrip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]

ASR-3001 acts as anon-selectiveagonist of theserotonin receptors.[6] This includes of theserotonin5-HT2A,5-HT2B,5-HT1A,5-HT1B, and5-HT6 receptors, whereas other serotonin receptors, such as the serotonin5-HT2C receptor, were not described.[6] ItsEC50Tooltip half-maximal effective concentration values were 9.85 nM at the serotonin 5-HT2A receptor, 46.8 nM at the serotonin 5-HT1B receptor, 87.4 nM at the serotonin 5-HT2B receptor, 420 nM at the serotonin 5-HT6 receptor, and 642 nM at the serotonin 5-HT1A receptor.[6] The drug was also a very weakserotonin reuptake inhibitor (IC50Tooltip half-maximal inhibitory concentration = 6,840 nM), but did notinhibitnorepinephrine ordopaminereuptake.[6] It showed little or no activity at various other sites as well.[6]

Chemistry

[edit]

Analogues

[edit]

Analogues of ASR-3001 (5-MeO-iPALT) includeisopropylallyltryptamine (iPALT; ASR-3003),5-MeO-DMT,5-MeO-DiPT,5-MeO-DALT,5-MeO-MiPT,5-MeO-EiPT,5-MeO-PiPT,5-MeO-MALT, and5-MeO-EPT, among others.[7] Other analogues includeASR-3002 (2-Me-iPALT), andASR-3004 (PALT), among others.[6]

History

[edit]

ASR-3001 was first described by 2023 and waspatented the same year.[1][6]

Society and culture

[edit]

Legal status

[edit]

Canada

[edit]

ASR-3001 is not an explicitly nor implicitlycontrolled substance inCanada as of 2025.[9]

United States

[edit]

ASR-3001 is not an explicitlycontrolled substance in theUnited States.[10] However, it could be considered a controlled substance under theFederal Analogue Act if intended for human consumption.

Research

[edit]

ASR-3001 is under development by the Nicholas V. Cozzi and Paul F. Daley and colleagues at theAlexander Shulgin Research Institute (ASRI).[5][1][4] As of early 2025, it is in thepreclinical research stage of development.[5][11] The drug is the ASRI's most advanced developmental candidate.[4]

See also

[edit]

References

[edit]
  1. ^abcdefghijkGoldstein L (10 July 2023)."Pioneering Psychedelics Scientist Alexander "Sasha" Shulgin's Legacy Lives On Via New Compounds And Research".Benzinga. Retrieved19 April 2025.
  2. ^abcdBusby M (2 November 2023)."The Heirs to a Vault of Novel Psychedelics Take a Trip Into the Unknown".DoubleBlind Mag. Retrieved19 April 2025.
  3. ^abcdBusby M (30 March 2025)."What Happens When You Inherit 500 Psychedelic Compounds?".DoubleBlind Mag. Retrieved19 April 2025.
  4. ^abcdefghijJoe Moore (2 April 2024)."Shulgin Farm and the Future of Psychedelic Drug Development (Featuring: Paul F. Daley, Ph.D.)" (Podcast). Psychedelics Today. Event occurs at 16:12–20:45.Our most advanced compound right now is a tryptamine that's orally active, fast-onset, the latent period before you start to feel effects is as little as 6 to 8 minutes, relatively short-acting, 90 minutes to two and a half hours, and satisfyingly internally psychedelic as opposed to entactogenic. But interestingly no visual involvement. So there are no open-eyed, closed-eyed visuals, that aspect is just not present. [...] We think that there's probably a subset of patients who are, for whatever reason, reluctant to get into a full-immersion psychedelic experience, at least initially. So once they're more familiar with the territory, something like a psilocybin experience, something more intense and all-encompassing might be more easily tolerated if there are some training wheels in advance. So we think that compound has that role.
  5. ^abc"Delving into the Latest Updates on Tryptamine(ASRI) with Synapse".Synapse. 16 April 2025. Retrieved19 April 2025.
  6. ^abcdefghiWO patent 2023034645A2, Paul Daley; Nicholas Cozzi & Wyeth Baillie Callaway, "Asymmetric allyl tryptamines", published 9 March 2023, assigned toAlexander Shulgin Research Institute 
  7. ^abShulgin A,Shulgin A (September 1997).TiHKAL: The Continuation.Berkeley, California:Transform Press.ISBN 0-9630096-9-9.OCLC 38503252.
  8. ^Shulgin A,Shulgin A (September 1991).PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press.ISBN 0-9630096-0-5.OCLC 25627628.
  9. ^"Controlled Drugs and Substances Act".Department of Justice Canada. 5 December 2025. Retrieved20 January 2026.
  10. ^Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026)(PDF),United States: U.S.Department of Justice:Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
  11. ^Michael Haichin (2024)."Psychedelics Drug Development Tracker".Psychedelic Alpha. Retrieved29 January 2025.

External links

[edit]
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT3–7
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Tryptamines
4-Hydroxytryptamines
andesters/ethers
5-Hydroxy- and
5-methoxytryptamines
N-Acetyltryptamines
α-Alkyltryptamines
α-Ketotryptamines
Cyclized tryptamines
Isotryptamines
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=ASR-3001&oldid=1338229862"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2026 Movatter.jp